Clinical Trials Update. 2013: Year in Review

  title={Clinical Trials Update. 2013: Year in Review},
  author={Stephen J. Peroutka},
  journal={Headache: The Journal of Head and Face Pain},
  • S. Peroutka
  • Published 1 January 2014
  • Psychology, Medicine
  • Headache: The Journal of Head and Face Pain
This section of Headache annually reviews the status of recently completed and ongoing major clinical trials involving common headache disorders. The review will focus on multicenter trials of new therapies, as well as novel formulations of previously approved therapeutics. Table 1 summarizes the major therapeutic headache trials that are ongoing at the present time, according to data obtained from both the “ClinicalTrials.Gov” website and from corporate press releases and presentations. 
6 Citations
Burning Mouth Syndrome Related to the Intake of Topiramate
Two women aged 36 and 38, who were evaluated in the neurology department of Virgen Macarena Hospital, reported experiencing long-standing migraines without aura required preventive treatment of topiramate, and it was concluded that the active ingredient was the cause of Burning Mouth Syndrome.
BMS-927711 for the acute treatment of migraine
  • M. Bigal
  • Medicine
    Cephalalgia : an international journal of headache
  • 2014
The result of a large Phase 2b study testing BMS-927711 for the acute treatment of migraine showed that the drug was clearly effective at multiple doses, meaning that all CGRP receptor antagonists tested to date have demonstrated efficacy in Phase 2 and Phase 3 studies.
Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity
An overview of the role of CGRP in the pathophysiology of migraine is provided, followed by a review of the clinical development of CgrP-RAs, and some basic concepts on antibodies are discussed along with the publicly disclosed information on the development of mAbs targeting the C GRP pathway.
Calcitonin Gene‐Related Peptide (CGRP) and Migraine Current Understanding and State of Development
The role of C GRP in normal physiology and the consequences of CGRP inhibition for human homeostasis are discussed and the current state of development for CGRp‐receptor antagonists and CGRPs monoclonal antibodies is reviewed.